Cebranopadol
Cebranopadol is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target mu-type opioid receptor, delta-type opioid receptor, nociceptin receptor, and kappa-type opioid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | HP_0012532 | — | — | 2 | 2 | — | — | 4 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | 1 | 2 | — | — | 4 |
| Neoplasms | D009369 | — | C80 | — | — | 2 | — | — | 2 |
| Acute pain | D059787 | — | R52 | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 3 | — | — | — | 3 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 2 | — | — | — | 2 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 2 | — | — | — | 2 |
| Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | 2 | — | — | — | 2 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | — | 1 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 1 | — | — | — | 1 |
| Back pain | D001416 | HP_0003418 | M54 | — | 1 | — | — | — | 1 |
| Postoperative pain | D010149 | — | G89.18 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | — | — | — | — | 2 |
| Hypercapnia | D006935 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cebranopadol |
| INN | cebranopadol |
| Description | Cebranopadol (developmental code GRT-6005) is an opioid analgesic of the benzenoid class which is currently under development internationally by Grünenthal, a German pharmaceutical company, and its partner Depomed, a pharmaceutical company in the United States, for the treatment of a variety of different acute and chronic pain states. As of November 2014, it is in phase III clinical trials.
|
| Classification | Small molecule |
| Drug class | analgesics (mixed opiate receptor agonists/antagonists) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12 |
Identifiers
| PDB | — |
| CAS-ID | 863513-91-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2364605 |
| ChEBI ID | — |
| PubChem CID | 11848225 |
| DrugBank | DB12830 |
| UNII ID | 7GDW9S3GN3 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
OPRM1
OPRM1
OPRD1
OPRD1
OPRL1
OPRL1
OPRK1
OPRK1
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 174 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use